Reusable Lancing Device Market Global Report 2026

The reusable lancing device market size has grown strongly in recent years. It will grow from $14.43 billion in 2025 to $15.85 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rising prevalence of diabetes worldwide, increasing awareness regarding regular blood glucose monitoring, growth in hospital and diagnostic testing volumes, advancements in lancet and lancing device safety features, expanding access to diabetes management programs.

The reusable lancing device market size is expected to see rapid growth in the next few years. It will grow to $23.25 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to growing adoption of home healthcare monitoring solutions, increasing demand for patient centric blood sampling devices, expansion of preventive healthcare screening programs, rising healthcare expenditure in emerging economies, development of more ergonomic and user friendly reusable lancing devices. Major trends in the forecast period include increasing adoption of safety engineered lancing devices for needlestick injury prevention, growing demand for adjustable depth lancing devices for personalized blood sampling, rising preference for reusable lancing devices to reduce long term monitoring costs, expansion of home based blood glucose monitoring practices, development of low pain blood sampling technologies for improved patient comfort.

The increasing global prevalence of diabetes is expected to drive the growth of the reusable lancing device market going forward. Diabetes is a chronic metabolic condition that occurs when the body is unable to properly regulate blood glucose levels due to inadequate insulin production or reduced insulin effectiveness. The growing prevalence of diabetes worldwide is being driven by rising obesity rates associated with sedentary lifestyles and unhealthy dietary patterns. Reusable lancing devices support diabetes management by providing patients who require frequent testing with convenient, accurate, and cost-efficient blood glucose monitoring solutions. For instance, in April 2024, according to the International Diabetes Federation, a Belgium-based non-profit diabetes organization, the number of adults living with diabetes reached 589 million in 2024 and is expected to rise to 853 million by 2050, reflecting an estimated increase of nearly 44.8%. Therefore, the rising global prevalence of diabetes is contributing to the growth of the reusable lancing device market.

Major companies operating in the reusable lancing device market are increasingly focusing on developing advanced, user-friendly blood sampling technologies, such as cap-free reusable lancing systems with concealed-needle mechanisms, to enhance patient comfort, simplify blood collection processes, and improve convenience in diabetes self-monitoring. Cap-free reusable lancing systems are blood sampling devices designed for multiple uses that eliminate the requirement for a protective cap, enabling users to directly cock and activate the lancing mechanism for faster and more convenient operation. For instance, in June 2025, SteriLance Medical, a China-based medical device manufacturer, launched the Onestep Lancing Device in Europe. The reusable lancing device incorporates a cap-free design and hidden-needle technology that minimizes preparation steps during blood sampling procedures. The system is developed to enable safer and more convenient capillary blood collection while enhancing usability for diabetes patients performing routine self-monitoring of blood glucose (SMBG). The launch expands the company’s diabetes care portfolio by addressing the growing demand for simplified and patient-focused reusable lancing solutions in home healthcare environments.

In March 2024, Medical Technology and Devices (MTD), an Italy-based manufacturer of medical devices and diabetes care solutions, acquired the pen needle and blood glucose monitoring (BGM) businesses of Ypsomed Holding AG for an undisclosed amount. Through this acquisition, Medical Technology and Devices (MTD) sought to strengthen its global diabetes care portfolio by expanding its blood glucose monitoring capabilities, increasing pen needle manufacturing capacity, and reinforcing its position in the diabetes self-care market. Ypsomed Holding AG is a Switzerland-based developer of diabetes care solutions, including blood glucose monitoring systems, pen needles, insulin delivery devices, and self-management technologies for diabetes patients.

Major companies operating in the reusable lancing device market report are F. Hoffmann-La Roche AG, Abbott Laboratories, Becton Dickinson and Company, B. Braun SE, Terumo Corporation, Nipro Corporation, Ascensia Diabetes Care Holdings AG, ARKRAY Inc., MED TRUST Handelsges.m.b.H., TaiDoc Technology Corporation, Bionime Corporation, Visiomed Group SA, Norditalia Elettromedicali S.r.l., Pharma Supply Inc., KETO-MOJO, LaMeditech Co. Ltd., Nova Diabetes Care, MHC Medical Products LLC, Owen Mumford Ltd., Boen Healthcare Co. Ltd., LifeScan Inc., AgaMatrix Inc., GlucoRx Ltd., Osang Healthcare Co. Ltd., Major Bioscience Co. Ltd.

North America was the dominating region in the reusable lancing device market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the reusable lancing device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the reusable lancing device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.